{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:53:18Z","timestamp":1793717598889,"version":"4.6.1"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/jjco\/hyy082","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T07:10:55Z","timestamp":1526627455000},"page":"703-711","source":"Crossref","is-referenced-by-count":54,"title":["New developments in systemic therapy for advanced biliary tract cancer"],"prefix":"10.1093","volume":"48","author":[{"given":"Chigusa","family":"Morizane","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Hepatobiliary and Pancreatic medical oncology Division, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Hepatobiliary and Pancreatic medical oncology Division, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"key":"key\n\t\t\t\t20180724061912_hyy082C1","volume-title":"General Rules for Clinical and Pathological Studies on Cancer of the Biliary Tract","author":"Japanese Society of Hepato-Biliary-Pancreatic Surgery","year":"2013","edition":"6th edn"},{"key":"key\n\t\t\t\t20180724061912_hyy082C2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","article-title":"S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study","volume":"62","author":"Furuse","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-009-1115-5","article-title":"Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer","volume":"65","author":"Sasaki","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00280-013-2090-4","article-title":"A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer","volume":"71","author":"Sasaki","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/cas.12218","article-title":"Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805)","volume":"104","author":"Morizane","year":"2013","journal-title":"Cancer Sci"},{"key":"key\n\t\t\t\t20180724061912_hyy082C8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2018.36.4_suppl.205","article-title":"Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: a Japan Clinical Oncology Group study (JCOG1113)","volume":"36","author":"Morizane","year":"2018","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00280-014-2648-9","article-title":"A multi-institution phase II study of gemcitabine\/cisplatin\/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)","volume":"75","author":"Kanai","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C13","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/jco.2015.33.15_suppl.4071","article-title":"Randomized phase II crossover trial exploring the clinical benefit from targeting EGFR or VEGF with combination chemotherapy in patients with non-resectable biliary tract cancer","volume":"33","author":"Jensen","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C15","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1200\/jco.2015.33.15_suppl.4082","article-title":"Panitumumab in combination with gemcitabine\/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: a randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"33","author":"Vogel","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C16","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C18","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2017.35.15_suppl.4016","article-title":"SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study","volume":"26","author":"Santoro","year":"2015","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C20","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180724061912_hyy082C22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180724061912_hyy082C24","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C26","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C27","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180724061912_hyy082C28","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20180724061912_hyy082C29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180724061912_hyy082C30","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180724061912_hyy082C31","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2017.35.15_suppl.4015","article-title":"Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts","volume":"35","author":"Lowery","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J Hematol Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2017.35.4_suppl.402","article-title":"Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway","volume":"35","author":"Javle","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20180724061912_hyy082C35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","article-title":"Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation","volume":"14","author":"Gingras","year":"2016","journal-title":"Cell Rep"},{"key":"key\n\t\t\t\t20180724061912_hyy082C36","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180724061912_hyy082C37","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C38","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C41","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180724061912_hyy082C42","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0959-8049(16)30326-4","article-title":"Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028","volume":"51","author":"Bang","year":"2015","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C43","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/annonc\/mdt337","article-title":"Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian group of digestive oncology","volume":"24","author":"Borbath","year":"2013","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C44","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C45","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1016\/j.ejca.2013.07.143","article-title":"Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study","volume":"49","author":"Rubovszky","year":"2013","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C46","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mds008","article-title":"Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer","volume":"23","author":"Jensen","year":"2012","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/bjc.2014.343","article-title":"Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer","volume":"111","author":"Hezel","year":"2014","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C48","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma","volume":"24","author":"Sohal","year":"2013","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2011-0253","article-title":"Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101","volume":"17","author":"Chiorean","year":"2012","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180724061912_hyy082C50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C51","article-title":"A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer","author":"Iyer","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C52","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2017.35.4_suppl.290","article-title":"A phase I\/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)","volume":"35","author":"Lowery","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C54","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C55","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C56","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","article-title":"Phase II study of erlotinib in patients with advanced biliary cancer","volume":"24","author":"Philip","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C57","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C59","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t20180724061912_hyy082C60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/jco.2015.33.3_suppl.343","article-title":"Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): safety, efficacy, and updated translational results","volume":"33","author":"Neuzillet","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C61","doi-asserted-by":"crossref","first-page":"v209","DOI":"10.1093\/annonc\/mdx369.106","article-title":"Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC)","volume":"28","author":"Ikeda","year":"2017","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C62","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1200\/JCO.2017.35.15_suppl.4081","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy refractory advanced and metastatic biliary adenocarcinoma\/cholangiocarcinoma","volume":"35","author":"Sun","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C63","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/cas.13438","article-title":"Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine","volume":"109","author":"Ikeda","year":"2018","journal-title":"Cancer Sci"},{"key":"key\n\t\t\t\t20180724061912_hyy082C65","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/annonc\/mdu175","article-title":"Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study","volume":"25","author":"Buzzoni","year":"2014","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C66","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1200\/jco.2014.32.15_suppl.4101","article-title":"Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol","volume":"32","author":"Yeung","year":"2014","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C67","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/jco.2016.34.4_suppl.335","article-title":"A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy","volume":"34","author":"Javle","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C68","doi-asserted-by":"crossref","first-page":"12122","DOI":"10.1038\/srep12122","article-title":"Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in patients with advanced biliary cancer","volume":"5","author":"Ahn","year":"2015","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180724061912_hyy082C69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clcc.2013.12.005","article-title":"A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers","volume":"13","author":"Denlinger","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C70","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C71","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t20180724061912_hyy082C72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00428-004-1046-9","article-title":"Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability","volume":"445","author":"Saetta","year":"2004","journal-title":"Virchows Arch"},{"key":"key\n\t\t\t\t20180724061912_hyy082C73","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180724061912_hyy082C74","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180724061912_hyy082C75","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers","volume":"206","author":"Nakazawa","year":"2005","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180724061912_hyy082C76","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180724061912_hyy082C77","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00428-015-1898-1","article-title":"A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status","volume":"468","author":"Yoshida","year":"2016","journal-title":"Virchows Arch"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/48\/8\/703\/25205630\/hyy082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T01:56:34Z","timestamp":1571363794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/48\/8\/703\/5035767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":77,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,6,11]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyy082","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,6,11]]}}}